SCHEDULING STATUS: S3

1. NAME OF THE MEDICINE

FELODIPINE 5 KIARA (tablets)
FELODIPINE 10 KIARA (tablets)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each FELODIPINE 5 KIARA film-coated extended-release tablet contains 5 mg felodipine.
Contains sugar (lactose monohydrate 46,25 mg).

Each FELODIPINE 10 KIARA film-coated extended-release tablet contains 10 mg felodipine.
Contains sugar (lactose monohydrate 92,5 mg).

Inactive ingredients: See Section 6.1 *List of excipients.*

3. PHARMACEUTICAL FORM
FELODIPINE 5 KIARA:
Round, biconvex, film-coated tablets; pale red to grey-red, embossment "F5" on one side of the tablet.
Diameter: 7,0 ± 0,3 mm; height: 2,3 to 3,1 mm.

FELODIPINE 10 KIARA:
Round, biconvex, film-coated tablets; pale red to grey-red, embossment "F10" on one side of the tablet.
Diameter: 9,0 ± 0,2 mm; height: 3,4 to 4,4 mm.

4. CLINICAL PARTICULARS
4.1. Therapeutic indications
FELODIPINE KIARA is indicated in the management of hypertension.

4.2. Posology and method of administration
Adults including the elderly:
The dose should be adjusted according to the individual requirements of the patient.
The recommended starting dose is 5 mg once daily.
The maintenance dose is 5 to 20 mg once daily.
In the elderly and in patients with impaired liver function the dose of felodipine tablets should, in general, not exceed 10 mg daily. The pharmacokinetics of felodipine is not significantly affected in patients with impaired renal function.
The tablets should be taken in the morning, swallowed with water and must not be divided, crushed or chewed.

FELODIPINE KIARA may be used in combination with diuretics or β-blockers. The effects on blood pressure are likely to be additive and combination therapy will usually enhance the antihypertensive effect. Care should be taken to avoid hypotension.

Children:
The safety and efficacy of FELODIPINE KIARA in children have not been established.

4.3. Contraindications

FELODIPINE KIARA should not be used in women of child-bearing potential (refer Section 4.6 *Fertility, pregnancy and lactation*), or in persons hypersensitive to felodipine.

Patients with cardiogenic shock.

4.4. Special warnings and precautions for use
FELODIPINE KIARA may precipitate significant hypotension with tachycardia. In susceptible individuals this may result in myocardial ischaemia.

Lactose intolerance
This medicine contains in each dosage unit:
• FELODIPINE 5 KIARA – lactose monohydrate 46,25 mg
• FELODIPINE 10 KIARA – lactose monohydrate 92,5 mg
Lactose is a source of glucose and galactose. Patients with the rare genetic disorders galactosaemia, or glucose-galactose intolerance, or congenital lactase deficiency should not take FELODIPINE KIARA.

4.5. Interaction with other medicines and other forms of interaction
Enzyme inhibitors such as cimetidine, erythromycin and certain flavonoids present in grapefruit juice, impair the elimination of felodipine and the dosage of felodipine tablets may need to be reduced when such active ingredients are given concomitantly.
Conversely, powerful enzyme-inducing agents such as some anticonvulsants (e.g. phenytoin, carbamazepine and phenobarbitone) can increase the elimination of felodipine and higher than normal doses of felodipine tablets may be required in patients taking such medicines.

No dosage adjustment is required when felodipine tablets are given concomitantly with digoxin.

The high degree of plasma protein binding of felodipine does not appear to affect the unbound fraction of other extensively bound medicines, such as warfarin.

4.6. Fertility, pregnancy and lactation
FELODIPINE KIARA should not be used in women of child-bearing potential (see Section 4.3 *Contraindications*).
FELODIPINE KIARA should not be used during pregnancy.
It is not known whether felodipine is excreted in breast milk or whether it has harmful effects on the new-born.

4.7. Effects on ability to drive and use machines
FELODIPINE KIARA may cause dizziness, fatigue and lethargy. Caution is recommended as the ability to perform skilled tasks, drive, or operate machinery may be impaired (see Section 4.8 *Undesirable effects*).

4.8. Undesirable effects
Immune system disorders:
*Frequency unknown:** There have been reports of rashes, fever, and abnormalities in liver function due to hypersensitivity reactions.
[* Cannot be reliably estimated from available data.]

Psychiatric disorders:
Frequency unknown: Mental depression has been reported.

Nervous system disorders:
Frequency unknown: Dizziness, flushing, headache, fatigue, lethargy.

Eye disorders:
Frequency unknown: Eye pain.

Vascular disorders:
Frequency unknown: Hypotension and peripheral oedema may occur.
A paradoxical increase in ischaemic chest pain may occur at the start of treatment and in a few patients, excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness.

Gastrointestinal disorders:
Frequency unknown: Gastrointestinal disturbances. Gingival hyperplasia has been reported but is often reversible on drug withdrawal.

Renal and urinary disorders:
Frequency unknown: Increased micturition frequency has been reported.
Sexual dysfunction/impotence occurs rarely.

4.9. Overdose
Overdosage may cause excessive peripheral vasodilation and marked hypotension, which may be accompanied by bradycardia. Severe hypotension should be treated symptomatically with the patient placed supine and the legs elevated. Bradycardia, if present, should be treated with atropine 0,5 to 1 mg intravenously. If this is not sufficient, plasma volume should be increased by infusion with e.g., glucose, normal saline or dextran solutions. Sympathomimetic drugs with a predominant effect on the α_1-adrenoceptor may be given, e.g., metaraminol or phenylephrine.

5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic properties
Pharmacological classification:
A 7.1 Vasodilators - Hypotensive medicines
ATC Code: C08CA02 - Dihydropyridine derivatives

Felodipine is a dihydropyridine Class A calcium antagonist which lowers the arterial blood pressure by decreasing vascular resistance. Felodipine exhibits *in vitro* selectivity for smooth muscle in the arterioles and, in therapeutic doses, has no direct effect on cardiac contractility. Felodipine does not affect venous smooth muscle or adrenergic vasomotor control. Electro-physiological studies have shown that felodipine has no direct effect on conduction in the specialised conducting system of the heart and no effect on the AV nodal refractoriness. Felodipine produces an increase in heart rate which is counteracted when concurrent β-receptor blockers are administered.
Felodipine has a mild natriuretic, diuretic and kaliuretic effect during the first few weeks of therapy.

5.2. Pharmacokinetic properties
Felodipine is approximately 99 % plasma protein bound (mainly albumin). Felodipine is well absorbed (almost completely) from the gastrointestinal tract after oral administration. Extensive first–pass metabolism results in a bioavailability of about 15 % (range 10 to 25 %). It is extensively metabolised in the gut and the liver and is excreted almost entirely as metabolites. About 70 % of an oral dose is excreted in the urine and the remainder in the faeces.
The terminal elimination half-life is reported to be between 11 to 16 hours following oral administration of an immediate–release preparation but longer with a modified release formulation.

6. PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Ferric oxide yellow, ferric oxide red, hydroxypropylmethylcellulose, lactose monohydrate, macrogol 4000, magnesium stearate, microcrystalline cellulose, sodium lauryl sulphate, titanium dioxide.

6.2. Incompatibilities
Not applicable.

6.3. Shelf life
36 months if stored at or below 25 °C in well-closed containers. Protect from light. Do not remove the blisters from the outer carton until required for use.

6.4. Special precautions for storage
This medicine does not require any special storage conditions.

6.5. Nature and contents of container
FELODIPINE 5 KIARA:
White, opaque PVC/aluminium blisters or white, opaque PVC/PVDC/aluminium blisters with 30 and 100 tablets.

FELODIPINE 10 KIARA:
White, opaque PVC/aluminium blisters or white, opaque PVC/PVDC/aluminium blisters with 30 and 100 tablets.

6.6. Special precautions for disposal
No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION
Kiara Health (Pty) Ltd
72 Steel Road, Spartan,
Kempton Park, 1619
South Africa

8. REGISTRATION NUMBER(S)
FELODIPINE 5 KIARA: 36/7.1/0302
FELODIPINE 10 KIARA: 35/7.1/0231

9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
FELODIPINE 5 KIARA: 30 October 2008
FELODIPINE 10 KIARA: 11 February 2013

10. DATE OF REVISION OF THE TEXT
24 May 2021

Additional countries registration details:

Country	Product name	Scheduling status (or Category of distribution)	Registration Number
Botswana	FELODIPINE 5 KIARA (30 Tablets)	S2	BOT1202231
	FELODIPINE 5 KIARA (100 Tablets)	S2	BOT1202231A
	FELODIPINE 10 KIARA (30 Tablets)	S2	BOT1302317
Namibia	FELODIPINE 5 KIARA	NS2	05/7.1/0298
	FELODIPINE 10 KIARA	NS2	06/7.1/0146

ATC Code: C08CA02 - Dihydropyridine derivatives

Name and address of manufacturer:
Salutas Pharma GmbH
Otto-von-Guericke-Alle 1
39179 Barleben,
Germany

02/21/FEL-009
51010007
V1 (11/01/2021)

SKEDULERINGSTATUS: S3

1. NAAM VAN DIE MEDISYNE

FELODIPINE 5 KIARA (tablette)
FELODIPINE 10 KIARA (tablette)

2. KWALITATIEWE EN KWANTITATIEWE SAMESTELLING
Elke FELODIPINE 5 KIARA filmbedekte verlengdevrystelling-stablet bevat 5 mg felodipien.
Bevat suiker (laktosemonohidraat 46,25 mg).

Elke FELODIPINE 10 KIARA filmbedekte verlengdevrystelling-stablet bevat 10 mg felodipien.
Bevat suiker (laktosemonohidraat 92,5 mg).

Onaktiewe bestanddele: Sien Afdeling 6.1 *Lys van eksipiënte*.

3. FARMASEUTIESE VORM
FELODIPINE 5 KIARA:
Ronde, bikonvekse, filmbedekte tablette; bleekrooi tot grysrooi, met reliëf "F5" aan die een kant van die tablet.
Deursnit: 7,0 ± 0,3 mm; hoogte: 2,3 tot 3,1 mm.

FELODIPINE 10 KIARA:
Ronde, bikonvekse, filmbedekte tablette; bleekrooi tot grysrooi, met reliëf "F10" aan die een kant van die tablet.
Deursnit: 9,0 ± 0,2 mm; hoogte: 3,4 tot 4,4 mm.

4. KLINIESE BESONDERHEDE
4.1. Terapeutiese indikasies
FELODIPINE KIARA is aangedui vir die behandeling van hipertensie.

4.2. Posologie en metode van toediening
Volwassenes insluitende bejaardes:
Die dosis moet volgens die individuele vereistes van die pasiënt aangepas word.
Die aanbevole aanvangsdosis is 5 mg een maal daagliks.
Die instandhoudingsdosis is 5 tot 20 mg een maal daagliks.
In bejaardes en pasiënte met ingekorte lewerfunksie moet die dosis van felodipientablette oor die algemeen nie 10 mg daagliks oorskry nie. Die farmakokinetika van felodipien is nie beduidend in pasiënte met ingekorte renale funksie geaffekteer nie.
Die tablette moet in die oggend geneem word, met water afgesluk word en moenie verdeel, verkrummel of gekou word nie.

FELODIPINE KIARA mag in kombinasie met diuretika en β-blokkers gebruik word. Die uitwerking op die bloeddruk sal waarskynlik additief wees en kombinasieterapie sal meestal die antihipertensiewe effek versterk. Sorg moet gedra word om hipotensie te voorkom.

Kinders:
Die veiligheid en effektiwiteit van FELODIPINE KIARA in kinders is nie vasgestel nie.

4.3. Kontra-indikasies

FELODIPINE KIARA moenie in vrouens met die potensiaal om kinders te baar gebruik word nie (verwys Afdeling 4.6 *Fertiliteit, swangerskap en laktasie*); ook nie in persone wat hipersensitief vir felodipien is nie.

Pasiënte met kardiogene skok.

4.4 Spesiale waarskuwings en voorsorgmaatreëls vir gebruik
FELODIPINE KIARA mag beduidende hipotensie met tagikardie presipiteer. In vatbare individue mag dit tot miokardiale iskemie lei.

Laktose-intoleransie
Elke dosiseenheid van hierdie medisyne bevat:
• FELODIPINE 5 KIARA – laktosemonohidraat 46,25 mg
• FELODIPINE 10 KIARA – laktosemonohidraat 92,5 mg
Laktose is 'n bron van glukose en galaktose. Pasiënte met raar oorerflikheidsteurings galaktosemie, of glukose-galaktose-intoleransie, of kongenitale laktasetekort moenie FELODIPINE KIARA neem nie.

4.5. Interaksie met ander medisyne en ander vorms van interaksie
Ensieminhibeerders, soos simetidien, eritromisien en sekere flavonoïede wat in pomelosap teenwoordig is, kort die eliminasie van felodipien in en dit mag nodig wees om die dosering van felodipientablette te verminder wanneer sulke aktiewe bestandele gesamentlik gegee word.
Daarteenoor kan sterk ensiminduserende middels, soos sommige antikonvulsante (bv. fenitoïen, karbamasepien en fenobarbitoon) die eliminasie van felodipien verhoog en hoër as die normale dosisse van felodipientablette mag in pasiënte wat sulke medisyne neem, benodig word.
Geen dosisaanpassing word benodig wanneer felodipientablette saam met digoksien gegee word nie.
Die hoë mate van plasmaproteïenbinding van felodipien blyk nie om die ongebonde fraksie van ander hoogsgebonde middels, soos warfarien, te beïnvloed nie.

4.6. Fertiliteit, swangerskap en laktasie
FELODIPINE KIARA moenie in vrouens met die potensiaal om kinders te baar gebruik word nie (sien Afdeling 4.3 *Kontra-indikasies*).
FELODIPINE KIARA moenie tydens swangerskap gebruik word nie.
Dit is nie bekend of felodipien in borsmelk uitgeskei word en of dit skadelike gevolge in 'n pasgeborene het nie.

4.7. Effekte op die vermoë om te bestuur en masjiene te gebruik
FELODIPINE KIARA mag duiseligheid, moegheid en lusteloosheid veroorsaak. Omsigtigheid word aanbeveel aangesien die vermoë om vaardige take te verrig, te bestuur of masjiene te bedryf ingekort mag wees (sien Afdeling 4.8 *Ongewenste effekte*).

4.8. Ongewenste effekte
Immuunsisteemsteurings:
*Frekwensie onbekend:** Daar was melding gemaak van uitslae, koors en abnormale lewerfunksies vanweë hipersensitiwiteitsreaksies.
[* Kan nie betroubaar uit die beskikbare data geskat word nie.]

Psigiatriese steurings:
Frekwensie onbekend: Geestesdepressie is gerapporteer.

Senuweesisteemsteurings:
Frekwensie onbekend: Duiseligheid, blosing, hoofpyn, moegheid, lusteloosheid.

Oogsteurings:
Frekwensie onbekend: Oogpyn.

Vaskulêre steurings:
Frekwensie onbekend: Hipotensie en perifere edeem mag voorkom. 'n Paradoksale styging in iskemiese borskaspyn mag met die aanvang van behandeling voorkom en in 'n paar pasiënte het oormatige verlaging van die bloeddruk tot serebrale of miokardiale iskemie of kortstondige blindheid gelei.

Gastro-intestinale steurings:
Frekwensie onbekend: Gastro-intestinale versteurings. Tandvleishiperplasie is gerapporteer, maar is dikwels omkeerbaar met onttrekking van die middel.

Renale en urinêre steurings:
Frekwensie onbekend: Verhoogde frekwensie van miktirisie is gemeld. Seksuele disfunksie/ impotensie kom seldsaam voor.

4.9. Oordosis
Oordosis mag oormatige perifere vasodilatasie en beduidende hipotensie, wat deur bradikardie vergesel mag word, veroorsaak. Erge hipotensie moet simptomaties behandel word met die pasiënt wat in die liggende posisie geplaas moet word met die bene opgelig. Bradikardie, indien teenwoordig, moet met atropien 0,5 tot 1 mg intraveneus behandel word. Indien hierdie nie voldoende is nie, moet plasmavolume vermeerder word deur infusie met bv. glukose, normale saline of dekstranoplossings. Simpatomimetiese middels met 'n predominante invloed op die α_1-adrenoseptor, bv. metaraminol of fenielefrien, mag gegee word.

5. FARMAKOLOGIESE EIENSKAPPE
5.1. Farmakodinamiese eienskappe
Farmakologiese klassifikasie:
A 7.1 Vasodilatore – Hipotensiewe geneesmiddels
ATC-Kode: C08CA02 - Dihidropiridienderivate

Felodipien is 'n dihidropiridien- Klas A kalsiumantagonis wat die arteriële bloeddruk verlaag deur vaskulêre weerstand te verminder. Felodipien vertoon *in vitro* selektiwiteit vir die gladdespier in arteriole en het, in terapeutiese dosisse, geen direkte effek op kardiale kontraktiliteit nie. Felodipien beïnvloed nie veneuse gladdespier of adrenergiese vasomotoriese beheer nie. Elektrofisiologiese studies het gewys dat felodipien geen direkte effek op geleiding in die gespesialiseerde geleidingsisteem van die hart het nie en geen effek op die AV-node se refraktoriteit nie. Felodipien bring 'n styging in harttempo mee wat deur die gepaardgaande toediening van β-reseptorblokkers teengewerk word.
Felodipien het 'n geringe natriuretiese, diuretiese en kaliuretiese effek gedurende die eerste paar weke van terapie.

5.2. Farmakokinetiese eienskappe
Felodipien is ongeveer 99 % aan plasmaproteïene (hoofsaaklik albumien) gebonde. Felodipien word goed (feitlik volledig) vanuit die gastro-intestinale kanaal na orale toediening geabsorbeer. Uitgebreide eerstedeurgangmetabolisme lei tot 'n biobeskikbaarheid van nagenoeg 15 % (reikwydte 10 tot 25 %). Dit word ekstensief in die dermkanaal en lewer gemetaboliseer en word amper geheel en al as metaboliete uitgeskei.
Ongeveer 70 % van 'n orale dosis word in die urine uitgeskei en die res in die feses.
Die terminale eliminasie-halfleeftyd is gerapporteer as tussen 11 tot 16 uur na orale toediening van 'n onmiddellikevrystelling-spreparaat, maar dit is langer met 'n gemodifiseerdevrystellingsformulering.

6. FARMASEUTIESE BESONDERHEDE
6.1. Lys van eksipiënte
Geel ferrioksied, rooi ferrioksied, hidroksipropielmetielsellulose, laktosemonohidraat, makrogol 4000, magnesiumstearaat, mikrokristallyne sellulose, natriumlourielsulfaat, titaandioksied.

6.2. Onverenigbaarhede
Nie van toepassing nie.

6.3. Raklewe
36 maande indien geberg teen of benede 25 °C in diggeslote houers. Beskerm teen lig. Moenie die stulpstroke uit die buitenste karton verwyder voordat nie vir gebruik benodig word nie.

6.4. Spesiale voorsorgmaatreëls vir berging
Hierdie medisyne benodig nie enige spesiale bergingstoestande nie.

6.5. Aard en inhoud van die houer
FELODIPINE 5 KIARA:
Wit, ondeursigtige PVC/aluminium-stulpstroke of wit, ondeursigtige PVC/PVDC/aluminium-stulpstroke met 30 en 100 tablette.

FELODIPINE 10 KIARA:
Wit, ondeursigtige PVC/aluminium-stulpstroke of wit, ondeursigtige PVC/PVDC/aluminium-stulpstroke met 30 en 100 tablette.

6.6. Spesiale voorsorgmaatreëls vir wegdoening
Geen spesiale vereistes nie.

7. HOUER VAN DIE SERTIFIKAAT VAN REGISTRASIE
Kiara Health (Pty) Ltd
72 Steel Road, Spartan,
Kempton Park, 1619
South Africa

8. REGISTRASIENOMMER(S)
FELODIPINE 5 KIARA: 36/7.1/0302
FELODIPINE 10 KIARA: 35/7.1/0231

9. DATUM VAN EERSTE MAGTIGING/HERNUWING VAN DIE MAGTIGING
FELODIPINE 5 KIARA: 30 Oktober 2008
FELODIPINE 10 KIARA: 11 Februarie 2013

10. DATUM VAN HERSIENING VAN DIE TEKS
24 Mei 2021

Bykomende lande se registrasiebesonderhede:

Land	Produknaam	Skedulering-status (of Kategorie van verspreiding)	Registrasie-nommer
Botswana	FELODIPINE 5 KIARA (30 Tablette)	S2	BOT1202231
	FELODIPINE 5 KIARA (100 Tablette)	S2	BOT1202231A
	FELODIPINE 10 KIARA (30 Tablette)	S2	BOT1302317
Namibië	FELODIPINE 5 KIARA	NS2	05/7.1/0298
	FELODIPINE 10 KIARA	NS2	06/7.1/0146

ATC-Kode: C08CA02 - Dihidropiridienderivate

Naam en adres van vervaardiger:
Salutas Pharma GmbH
Otto-von-Guericke-Alle 1
39179 Barleben,
Germany